Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 939
Filtrar
1.
BMC Oral Health ; 24(1): 469, 2024 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-38632580

RESUMEN

BACKGROUND: Oral leukoplakia (OLK) is a prevalent precancerous lesion with limited non-pharmacological treatment options. Surgery and various lasers are the mainstay of treatment; however, their relative efficacy and optimal choice remain unclear. This first network meta-analysis compared the effects of different lasers and surgical excision on post-treatment recurrence and comfort in OLK patients. METHODS: We searched four databases for relevant randomized controlled trials (RCTs) up to April 2023. The primary outcome was post-treatment recurrence, and secondary outcomes included intraoperative hemorrhage and postoperative pain scores. The Cochrane Risk of Bias tool was used to assess the study quality. Meta-analysis and network meta-analysis were employed to determine efficacy and identify the optimal intervention. RESULTS: A total of 11 RCTs including 917 patients and 1138 lesions were included. Er,Cr:YSGG laser treatment showed significantly lower recurrence rates compared to CO2 laser (OR: 0.04; 95% CI: 0.01-0.18), CO2 laser with margin extension (OR: 0.06; 95% CI: 0.01-0.60), Er:YAG laser (OR: 0.10; 95% CI: 0.03-0.37), electrocautery (OR: 0.03; 95% CI: 0.00-0.18), and standard care (OR: 0.08; 95% CI: 0.02-0.33). Er,Cr:YSGG laser also ranked the best for reducing recurrence, followed by standard care and CO2 laser combined with photodynamic therapy (PDT). Er:YAG and Er:Cr:YSGG lasers minimized bleeding and pain, respectively. None of the interventions caused severe adverse effects. CONCLUSION: For non-homogeneous OLK, Er:YAG, Er:Cr:YSGG, and CO2 laser combined with PDT offer promising alternatives to surgical excision, potentially reducing recurrence and improving patient comfort. Further high-quality RCTs are necessary to confirm these findings and determine the optimal laser-PDT combination for OLK treatment.


Asunto(s)
Terapia por Láser , Láseres de Estado Sólido , Humanos , Metaanálisis en Red , Dióxido de Carbono/uso terapéutico , Comodidad del Paciente , Leucoplasia Bucal , Láseres de Estado Sólido/uso terapéutico
2.
Rev. argent. cir. plást ; 30(1): 24-31, 20240000. fig, tab
Artículo en Español | LILACS, BINACIS | ID: biblio-1551309

RESUMEN

Pivoting Brow Lift es una nueva opción terapéutica cuyas ventajas son tres mínimas incisiones, prácticamente imperceptibles, bien aceptadas por pacientes de todas las edades, sexo y incluso pacientes calvos. Una incisión se realiza en la región temporal y otra dentro del cuero cabelludo en la región medio frontal o en una arruga en pacientes calvos. La disección en región frontal es sub-perióstica, muchas veces llega a la punta nasal para reposicionarla. La disección en la región temporal se realiza entre las hojas superficiales y profundas extendiéndose hasta el tarso y canto externo del ojo; en la región palpebral la disección se realiza entre la piel y el musculo. La fijación son dos puntos externos en el cuero cabelludo y unos papeles adherentes. Los puntos del cuero cabelludo se retiran a los 14 días. Evita las complejas fijaciones que se realizan actualmente con tornillos, puntos internos o Endotime. La sencillez del procedimiento hace que este se pueda realizar entre 30 y 45 minutos, con anestesia local y sedación; esto permite lograr una mayor seguridad operatoria. Se han documentado pacientes tratados hace 9 años donde se demuestra la duración en el tiempo. El bajo índice de complicaciones y la alta satisfacción de los pacientes documentadas en encuestas hace que este procedimiento pueda ser considerado como una nueva opción terapéutica.


Asunto(s)
Humanos , Masculino , Femenino , Rejuvenecimiento/fisiología , Dióxido de Carbono/uso terapéutico , Blefaroplastia/métodos , Terapia por Láser/métodos
3.
Environ Toxicol ; 39(5): 3188-3197, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38356236

RESUMEN

Yin chai hu (Radix Stellariae) is a root medicine that is frequently used in Chinese traditional medicine to treat fever and malnutrition. In modern medicine, it has been discovered to have anti-inflammatory, anti-allergic, and anticancer properties. In a previous study, we were able to extract lipids from Stellariae Radix using supercritical CO2 extraction (SRE), and these sterol lipids accounted for up to 88.29% of the extract. However, the impact of SRE on the development of atopic dermatitis (AD) has not yet been investigated. This study investigates the inhibitory effects of SRE on AD development using a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model. Treatment with SRE significantly reduced the dermatitis score and histopathological changes compared with the DNCB group. The study found that treatment with SRE resulted in a decrease of pro-inflammatory cytokines TNF-α, CXC-10, IL-12, and IL-1ß in skin lesions. Additionally, immunohistochemical analysis revealed that SRE effectively suppressed M1 macrophage infiltration into the AD lesion. Furthermore, the anti-inflammatory effect of SRE was evaluated in LPS + INF-γ induced bone marrow-derived macrophages (BMDMs) M1 polarization, SRE inhibited the production of TNF-α, CXC-10, IL-12, and IL-1ß and decreased the expression of NLRP3. Additionally, SRE was found to increase p-AMPKT172, but had no effect on total AMPK expression, after administration of the AMPK inhibitor Compound C, the inhibitory effect of SRE on M1 macrophages was partially reversed. The results indicate that SRE has an inhibitory effect on AD, making it a potential therapeutic agent for this atopic disorder.


Asunto(s)
Dermatitis Atópica , Animales , Ratones , Dermatitis Atópica/inducido químicamente , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/metabolismo , Dinitroclorobenceno/toxicidad , Dinitroclorobenceno/uso terapéutico , Proteínas Quinasas Activadas por AMP , Dióxido de Carbono/toxicidad , Dióxido de Carbono/uso terapéutico , Factor de Necrosis Tumoral alfa , Citocinas/metabolismo , Macrófagos/metabolismo , Antiinflamatorios/uso terapéutico , Interleucina-12/toxicidad , Interleucina-12/uso terapéutico , Lípidos , Ratones Endogámicos BALB C , Piel
4.
Hypertens Res ; 47(3): 760-766, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38177288

RESUMEN

The recent evidence regarding the effectiveness of renal denervation (RDN) in blood pressure control is becoming increasingly substantial. However, many studies have excluded populations with severely impaired kidney function, even though these individuals have a higher prevalence of hypertension compared to the general population, and controlling their blood pressure is more challenging. The effectiveness and safety of RDN in patients with severe chronic kidney disease (CKD) lack strong evidence support. Concerns about worsening kidney function still exist, particularly in patients with CKD stage 5. We conducted an observational study involving 10 patients who were using at least 3 different antihypertensive medications and had an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 but had not undergone dialysis. For these patients, we performed RDN via the radial artery approach, with the assistance of carbon dioxide (CO2) angiography. Utilizing this approach, the systolic 24-hour ambulatory blood pressure monitoring did not exhibit a significant decrease at 3 months; however, a significant reduction was observed at 6 months after RDN. We also minimized contrast agent usage, observed no kidney function decline 3 months post-RDN, and experienced no vascular-related complications. Using the radial artery approach and CO2 angiography assistance for RDN may be an effective and safe blood pressure control method for patients with severe kidney impairment.


Asunto(s)
Hipertensión , Insuficiencia Renal Crónica , Humanos , Dióxido de Carbono/uso terapéutico , Monitoreo Ambulatorio de la Presión Arterial , Estudios de Factibilidad , Arteria Radial/diagnóstico por imagen , Simpatectomía/métodos , Insuficiencia Renal Crónica/complicaciones , Riñón , Presión Sanguínea/fisiología , Angiografía , Resultado del Tratamiento , Desnervación
5.
Photodermatol Photoimmunol Photomed ; 40(1): e12944, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38288773

RESUMEN

BACKGROUND: Several treatment modalities are available for the treatment of vitiligo due to the lack of a uniformly effective therapy. Topical latanoprost 0.005% is an effective topical treatment. Fractional CO2 laser alone or combined with platelet-rich plasma (PRP) has been proposed as effective adjunctive therapies. OBJECTIVES: We aimed to compare the efficacy of topical latanoprost 0.005% (Ioprost®, Orchidia, Egypt) combined with either add-on fractional CO2 laser or fractional CO2 -PRP versus topical latanoprost monotherapy in the treatment of localized stable vitiligo. PATIENTS/METHODS: The study included 60 patients randomly assigned into three equal groups. Group A patients received topical latanoprost drops only. Group B patients received topical latanoprost drops and fractional CO2 laser sessions at 2-week interval for 3 months. Group C patients received topical latanoprost drops and fractional CO2 laser sessions combined with PRP at a 2-week interval for 3 months. The mean improvement score by the physician was calculated 4 months after the start of the study. Punch skin biopsies were obtained before treatment and 4 months from the beginning of the study and stained with H&E and HMB-45 antibody for evaluation of pigmentation. RESULTS: Significant clinical improvement of vitiligo lesions with significant increase of re-pigmentation were reported in the three treated groups. Latanoprost in combination with fractional CO2 and PRP was associated with more significant therapeutic outcomes than either combined latanoprost and fractional CO2 or latanoprost alone. CONCLUSION: Fractional CO2 laser-PRP enhances the therapeutic efficacy of latanoprost 0.005% in the treatment of localized stable vitiligo.


Asunto(s)
Láseres de Gas , Plasma Rico en Plaquetas , Vitíligo , Humanos , Dióxido de Carbono/uso terapéutico , Terapia Combinada , Rayos Láser , Láseres de Gas/uso terapéutico , Latanoprost/uso terapéutico , Resultado del Tratamiento , Vitíligo/tratamiento farmacológico
6.
Clin Oral Investig ; 27(12): 7753-7763, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37999801

RESUMEN

OBJECTIVE: This in situ study aimed to investigate the efficacy of CO2 laser at a 10.6-µm wavelength combined with 1.23% acidulated phosphate fluoride (APF) and fluoridated dentifrice with 1100 µg F/g (FD) to control enamel caries progression. MATERIALS AND METHODS: Sixteen volunteers wore palatal appliances containing eight demineralized enamel specimens for four 14-day phases under sucrose exposure. These specimens were submitted to CO2 laser irradiation and APF alone or combined with FD. Treatment groups were non-fluoridated dentifrice-NFD, NFD + CO2 laser, NFD + APF, NFD + CO2 laser + APF, FD, FD + CO2 laser, FD + APF, and FD + CO2 laser + APF. Mineral loss, calcium fluoride (CaF2), fluorapatite (FAp), and fluoride in the biofilm were analyzed by analysis of variance followed by the Student-Newman-Keuls test, p < 0.05. RESULTS: The highest mineral loss inhibition was noted when FD and CO2 laser irradiation were combined, which did not significantly differ from the FD + CO2 laser + APF group. The CaF2, FAp, and F in the biofilm were more pronounced when the FD and APF were combined. The CO2 laser irradiation promoted a slightly higher concentration of CaF2 in the enamel and F in the biofilm. CONCLUSION: Although APF promotes the high formation of CaF2 and FAp, the combined use of FD with CO2 laser overcomes the APF effect in inhibiting the progression of artificial caries-like lesions in situ. CLINICAL SIGNIFICANCE: Under the in situ design of this study, remineralization of white spot lesions was achieved through CO2 laser irradiation and daily use of fluoridated dentifrice. Future clinical trials are encouraged to substantiate this finding.


Asunto(s)
Caries Dental , Dentífricos , Láseres de Gas , Desmineralización Dental , Humanos , Fluoruro de Fosfato Acidulado/uso terapéutico , Fluoruro de Fosfato Acidulado/farmacología , Dentífricos/uso terapéutico , Dentífricos/farmacología , Dióxido de Carbono/uso terapéutico , Cariostáticos/uso terapéutico , Susceptibilidad a Caries Dentarias , Caries Dental/prevención & control , Caries Dental/tratamiento farmacológico , Fluoruros/uso terapéutico , Apatitas , Láseres de Gas/uso terapéutico , Desmineralización Dental/prevención & control
7.
Photodiagnosis Photodyn Ther ; 43: 103700, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37429461

RESUMEN

BACKGROUND: Photodynamic therapy (PDT) for actinic keratosis (AK) is limited by the depth of treatment. Microneedling or fractional CO2 laser can facilitate the penetration of photosensitizer, while cryotherapy can treat deeper tissues but is not suitable for field cancerization. OBJECTIVE: To investigate the efficacy of microneedling, fractional CO2 laser, and cryotherapy in combination with PDT for AK. METHODS: Patients with AK were randomized into 4 groups, including group A with microneedling + PDT, group B with fractional CO2 laser + PDT, group C with cryotherapy + PDT, and group D with PDT. After 12 weeks, the clinical, dermoscopic, and reflectance confocal microscopy (RCM) outcomes were assessed. RESULTS: A total of 129 patients were included in this study, with 31, 30, 35, and 31 patients in each group, yielding clinical response rates of 90.3%, 93.3%, 97.1%, and 74.2%, respectively (P=0.026). The RCM response rates were 71.0%, 80.0%, 85.7%, and 54.8%, respectively (P=0.030). The dermoscopic response rates were 77.4%, 83.3%, 88.6%, and 60.0%, respectively (P=0.039). Group C showed the best efficacy in terms of clinical, dermoscopic, and RCM outcomes. CONCLUSIONS: All three treatments improved the efficacy of PDT and were well tolerated, with cryotherapy + PDT showing the best efficacy.


Asunto(s)
Queratosis Actínica , Láseres de Gas , Fotoquimioterapia , Humanos , Ácido Aminolevulínico , Queratosis Actínica/tratamiento farmacológico , Fármacos Fotosensibilizantes , Dióxido de Carbono/uso terapéutico , Estudios Prospectivos , Fotoquimioterapia/métodos , Crioterapia , Láseres de Gas/uso terapéutico , Resultado del Tratamiento
8.
J Cosmet Dermatol ; 22(9): 2464-2470, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37417644

RESUMEN

BACKGROUND: Fractional carbon dioxide (CO2 ) laser resurfacing is used successfully for facial rejuvenation. Post procedure skincare is a variable that influences downtime caused by pain/tenderness, erythema, crusting, and bruising. AIMS: The primary objective of this pilot study was to demonstrate the benefits of human platelet extract (HPE) (plated)™ CALM Serum, a new topical cosmetic product, following fractionated CO2 ablative laser resurfacing treatment to the entire face versus standard of care. METHODS: In a single-center, randomized, evaluator-blinded pilot study, a total of 18 subjects were randomized into two groups, CO2 facial resurfacing followed by post-procedural standard of care (Stratacel silicone gel) or CO2 facial resurfacing with the addition of HPE renewosomes in the CALM Serum. RESULTS: CALM Serum demonstrated statistically significant less crusting at Day 10 compared to the control group (p = 0.0193) with less downtime in the first 14 days (p = 0.03). Subjects treated with CALM Serum had statistically significant brighter appearing skin at 14 days (p = 0.007) and more youthful looking skin on Days 14 and 30 (p = 0.003 and 0.04, respectively). CONCLUSIONS: This study demonstrates that Renewosome™ technology provides statistically significant post-laser clinical recovery over silicone gel for reducing crusting, and downtime. Subjects reported less diary days of symptoms of pain/tenderness, redness, crusting/flaking, bruising, and itching in the first 14 days compared to the control group. CALM also demonstrated statistically significant improvements in brighter and more youthful appearing skin. CALM is safe and well tolerated.


Asunto(s)
Terapia por Láser , Láseres de Gas , Envejecimiento de la Piel , Humanos , Proyectos Piloto , Dióxido de Carbono/uso terapéutico , Geles de Silicona , Terapia por Láser/efectos adversos , Terapia por Láser/métodos , Resultado del Tratamiento , Eritema/etiología , Eritema/tratamiento farmacológico , Láseres de Gas/efectos adversos , Rejuvenecimiento
9.
Photodiagnosis Photodyn Ther ; 43: 103695, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37422201

RESUMEN

OBJECTIVE: To evaluate the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) and CO2 laser therapy of low-grade vaginal intraepithelial neoplasia (VAIN1) combined with high-risk human papillomavirus (hr-HPV) infection. METHODS: A total of 163 patients with VAIN1 and hr-HPV infection were divided into PDT Group (n = 83) and CO2 laser Group (n = 80). The PDT Group received six times of ALA-PDT treatments and the CO2 laser Group received once CO2 laser treatment. HPV types, cytology, colposcopy, and pathological examinations were carried out before and after treatment. The differences in HPV clearance rate, VAIN1 regression rate, and adverse reactions between the two groups were analyzed during 6-month follow-up. RESULTS: The overall HPV clearance rate of the PDT Group was significantly higher than that of the CO2 laser Group (65.06% vs 38.75%, P = 0.0008) although similar result was obtained for 16/18-related HPV infection patients (54.55% vs 43.48%, P = 0.4578). The VAIN1 regression rate of the PDT Group was significantly higher than that of the CO2 laser Group (95.18% vs 83.75%, P = 0.0170). In patients ≥ 50 years old, ALA-PDT showed better HPV clearance rate and VAIN1 regression rate than CO2 laser therapy (P < 0.05). The adverse reactions in the PDT Group were significantly lower than that in the CO2 laser Group (P > 0.05). CONCLUSIONS: The efficacy of ALA-PDT appears better than CO2 laser for VAIN1 patients. However, the long-term effect of ALA-PDT for VAIN1 still needs to be explored. As a non-invasive treatment, ALA-PDT is a highly effective therapeutic procedure for VAIN1 with hr-HPV infection.


Asunto(s)
Carcinoma in Situ , Láseres de Gas , Infecciones por Papillomavirus , Fotoquimioterapia , Neoplasias del Cuello Uterino , Femenino , Humanos , Persona de Mediana Edad , Fármacos Fotosensibilizantes/uso terapéutico , Infecciones por Papillomavirus/tratamiento farmacológico , Fotoquimioterapia/métodos , Dióxido de Carbono/uso terapéutico , Proyectos Piloto , Ácido Aminolevulínico/uso terapéutico , Carcinoma in Situ/tratamiento farmacológico , Láseres de Gas/uso terapéutico , Neoplasias del Cuello Uterino/tratamiento farmacológico
10.
Artículo en Ruso | MEDLINE | ID: mdl-37427823

RESUMEN

OBJECTIVE: To analyze the application efficacy of the carboxytherapy method with the aim of chronic pain syndrome reduction. MATERIAL AND METHODS: The available literature sources, published in the period from 2017 to 2022 yrs and indexed in international abstract databases Scopus, Web of Science and PubMed, have been analyzed. The search was done by following keywords: carboxytherapy, medical rehabilitation, chronic pain. The patient with chronic pain syndrome, who was treated by carboxytherapy during rehabilitation, was also observed, with a subsequent evaluation of the carboxytherapy application in comprehensive treatment. RESULTS: Analysis of available literature has shown that the different methodical variants of carboxytherapy are used to obtain analgesic, antispasmodic, anti-inflammatory and regenerative effects in patients with chronic pain. In the presented clinical case the use of carboxytherapy in the patient with chronic pain syndrome demonstrated the efficacy of technique, expressed in the positive dynamics in the evaluation of pain syndrome reduction on the visual analogue scale and the disability indicators in the Rollan Morris and Oswestry questionnaires. CONCLUSION: Carboxytherapy reduces the intensity of chronic pain syndrome and can be applied as an additional method in medical rehabilitation. Further studies in this direction are needed.


Asunto(s)
Dolor Crónico , Humanos , Dolor Crónico/tratamiento farmacológico , Resultado del Tratamiento , Dióxido de Carbono/uso terapéutico , Dimensión del Dolor
11.
Eur Arch Otorhinolaryngol ; 280(9): 4155-4163, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37261519

RESUMEN

OBJECTIVES: To investigate the clinical outcomes of morphology-guided surgical treatment for adult laryngeal and hypopharyngeal hemangioma. MATERIALS AND METHODS: Patients diagnosed with adult laryngeal and hypopharyngeal hemangioma by outpatient laryngoscopy and received surgical treatments were retrospectively included. Size and morphology were classified to guide the choose of surgical procedures including CO2 laser excision, CO2 coagulation + bleomycin injection and potassium-titanyl-phosphate (KTP) laser + bleomycin injection. The baseline information and pre-, postoperative laryngoscopies were collected, the outcomes were followed up and analyzed. RESULTS: A total of 68 patients were included, 7 cases with exophytic and non-bulky hemangioma received CO2 laser excision, 20 cases received CO2 laser coagulation + bleomycin injection and 25 cases with KTP + bleomycin injection, another 16 cases with pure bleomycin injection were included as comparison. There was no difference of baseline analysis among the groups (P > = 0.05). Positive outcomes were achieved in most cases of CO2 excision (100%), CO2 coagulation + bleomycin (90.0%) and KTP + bleomycin (84.0%) groups, which were better than pure bleomycin (56.3%, p = 0.001). CO2 or KTP, associated to Bleomycin, gave same results on same lesions (P = 0.132). CONCLUSIONS AND SIGNIFICANCE: Morphology of hemangioma may help in the selection of surgical procedures. CO2 coagulation can be used as a potential substitute for KTP in the treatment of adult laryngeal and hypopharyngeal hemangioma.


Asunto(s)
Hemangioma , Laringe , Terapia por Láser , Láseres de Estado Sólido , Humanos , Adulto , Estudios Retrospectivos , Dióxido de Carbono/uso terapéutico , Laringe/patología , Bleomicina/uso terapéutico , Hemangioma/cirugía , Hemangioma/tratamiento farmacológico , Terapia por Láser/métodos , Resultado del Tratamiento
12.
Lasers Med Sci ; 38(1): 139, 2023 Jun 16.
Artículo en Inglés | MEDLINE | ID: mdl-37326860

RESUMEN

Melasma is a chronic relapsing skin condition. Laser therapy is a new advancement in treatment. Whether the topical application of tranexamic acid (TXA) increases the efficacy of laser therapy in melasma is still under debate. With recent studies yielding different results, it was imperative to compile all the available literature systematically. This meta-analysis investigates the effectiveness of a combination therapy of laser plus TXA acid for treating melasma. PubMed/MEDLINE, Cochrane Central, Google Scholar, Scopus, and the International Clinical Trials registry were systematically searched for article retrieval. Screening per PRISMA guidelines was undertaken by two independent reviewers using the Covidance database. Melasma area of severity index (MASI)/modified MASI was used as the clinical improvement outcomes. A total of nine studies that described the combined use of topical tranexamic acid with laser therapy were included for meta-analysis. These studies employed various types of lasers along with topical TXA. The results showed that the combination of both laser therapy and topical TXA significantly decreased the MASI score (P < 0.0001). Subgroup analyses revealed that fractional CO2 laser among the laser types and monthly laser plus twice daily topical TXA were most effective in decreasing the MASI/mMASI score. The meta-analysis found that combining topical tranexamic acid and laser therapy is an effective and safer treatment option for treatment-resistant melasma. Furthermore, monthly fractional CO2 laser and daily application of topical tranexamic acid showed high effectiveness and safety.


Asunto(s)
Láseres de Gas , Melanosis , Ácido Tranexámico , Humanos , Dióxido de Carbono/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Láseres de Gas/uso terapéutico , Melanosis/tratamiento farmacológico , Resultado del Tratamiento
13.
Medicina (Kaunas) ; 59(6)2023 Jun 09.
Artículo en Inglés | MEDLINE | ID: mdl-37374321

RESUMEN

Background and Objectives: For many years, fully ablative laser treatments, particularly those performed with a carbon dioxide (CO2) laser, were regarded as the gold standard for resurfacing. This study's goal is to assess the depth that can be reached by a new CO2 scanner system, through a skin model with greater dermal thickness, to use in the treatment of deep scarring. Materials and Methods: Male human skin tissue was laser-treated using a CO2 fractional laser and a new scanning system, and all samples were fixed in 10% neutral buffered formalin, dehydrated using a series of crescent alcohol, embedded in paraffin, sectioned in series (4-5 µm thick), stained with haematoxylin and eosin (H&E), and then analysed under an optical microscope. Results: From the epidermis through the underlying papillary and reticular dermis to various depths of the dermis, microablation columns of damage and coagulated microcolumns of collagen were observed. The reticular dermis was fully penetrated up to 6 mm at higher energy levels (210 mJ/DOT), resulting in deeper tissue injury. Although the laser might penetrate further, the skin stops there, leaving just the fat and muscular tissue. Conclusions: The deep layers of the dermis can be penetrated by the CO2 laser system throughout the entire dermal thickness when using the new scanning system, suggesting that this laser's potential impact, at the selected settings, covers all skin targets required to perform superficial or deep treatments on any dermatological issue. Finally, patients who have problems, such as morbid scar-deep complications, which affect their quality of life, are more likely to profit from this innovative technique.


Asunto(s)
Cicatriz , Láseres de Gas , Humanos , Masculino , Dióxido de Carbono/uso terapéutico , Calidad de Vida , Piel/patología , Dermis/patología , Láseres de Gas/uso terapéutico
14.
Lasers Med Sci ; 38(1): 147, 2023 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-37354212

RESUMEN

Onychomycosis is a fungal infection of the nail unit caused by various species of dermatophytes, non-dermatophytic moulds or yeasts. They pose a therapeutic challenge to the treating dermatologist as the infection is often resistant to treatment and requires prolonged therapy. To evaluate the efficacy and safety profile of fractional CO2 laser and 0.25% Amorolfine hydrochloride cream in the treatment of onychomycosis. In this randomized controlled study on 50 patients with fingernail onychomycosis, one group (25 patients, 30 nails) were treated with fractional CO2 laser and 0.25% Amorolfine hydrochloride cream, and the second group (25 patients, 31 nails) with oral itraconazole pulse therapy. Four treatment sessions were carried out in the first group at an interval of two weeks each. Whereas, the second group received 2 doses of itraconazole pulse therapy with one month interval each. Both the groups were followed up for a period of 4 months. Results were assessed by Onychomycosis severity index(OSI), Physician global assessment scale, patient's subjective score and fungal microscopy. Complete resolution was seen in 14 out of 25(56%) patients and 6 out of 25(24%) patients in group 1 and group 2 respectively. There was statistically significant difference in the response between the two groups during 1st and 2nd follow up (p value - 0.004 and 0.023 respectively). Fractional CO2 laser with amorolfine cream is proved to be a better modality in onychomycosis therapy compared to oral itraconazole pulse therapy, especially in distal lateral subungual and superficial white onychomycosis.


Asunto(s)
Láseres de Gas , Onicomicosis , Humanos , Itraconazol/uso terapéutico , Onicomicosis/tratamiento farmacológico , Antifúngicos/efectos adversos , Dióxido de Carbono/uso terapéutico , Láseres de Gas/efectos adversos , Resultado del Tratamiento
15.
Medicine (Baltimore) ; 102(21): e33696, 2023 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-37233420

RESUMEN

We compared the therapeutic effect of catheter direct thrombolysis (CDT) and peripheral venous thrombolysis (PVT) for patients with acute pulmonary embolism (APE). Totally, 74 patients with APE were enrolled, including 37 in the CDT group and 37 in the PVT group. The changes in clinical indicators pre and posttreatment were observed. Clinical efficacy was evaluated. Kaplan-Meier method was used to analyze the survival of patients during follow-up. In both the PVT group and CDT group, partial pressure of oxygen after treatment increased significantly than that before treatment (P < .05). However, in both groups, the levels of partial pressure of carbon dioxide, D-dimer, B-type brain natriuretic peptide, pulmonary arterial pressure, and thrombus volume after treatment were significantly decreased than those before treatment (P < .05). After treatment, patients from the CDT group had significantly lower D-dimers, partial pressure of carbon dioxide, brain natriuretic peptide, and pulmonary arterial pressure, and significantly higher partial pressure of oxygen compared to patients from the PVT group (P < .05). The total effective rate was 97.2% in the CDT group and 81.0% in the PVT group. The bleeding incidence in the CDT group was significantly lower than that in the PVT group (P < .05). The median survival time in the CDT group was significantly longer than that in the PVT group (P < .05). CDT can more effectively improve symptoms, cardiac function, and survival rate of APE patients while reducing bleeding incidence than PVT, and thus is safe and effective in treating APE.


Asunto(s)
Hominidae , Embolia Pulmonar , Humanos , Animales , Fibrinolíticos/uso terapéutico , Terapia Trombolítica/métodos , Dióxido de Carbono/uso terapéutico , Péptido Natriurético Encefálico/uso terapéutico , Embolia Pulmonar/terapia , Catéteres/efectos adversos , Hemorragia/etiología , Resultado del Tratamiento , Estudios Retrospectivos
16.
Am J Obstet Gynecol ; 229(3): 278.e1-278.e9, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37192705

RESUMEN

BACKGROUND: Postmenopausal vaginal symptoms affect over 60% of women and may substantially impact a woman's quality of life. Since 2012, fractional CO2 laser has been suggested as a treatment for this indication. Structural assessment of vaginal epithelium using microscopic biopsy examination has been used as a primary outcome measure and surrogate determinant of success of vaginal laser in previous clinical studies. OBJECTIVE: This study aimed to report the effects of laser compared with sham treatment on human vaginal epithelium from postmenopausal women using microscopic examination of tissue biopsies. STUDY DESIGN: This single-center double-blind, sham-controlled randomized controlled trial was performed in a tertiary hospital in Sydney, Australia. A total of 49 postmenopausal women who were symptomatic of at least 1 vaginal symptom (vaginal dryness, burning, itching; dyspareunia; or dryness) were randomized to either laser or sham treatment. For this nested histologic study, participants had a pre- and post-treatment vaginal wall biopsy collected. Biopsy samples were analyzed by 3 independent specialist gynecologic pathologists and categorized as Type 1 (well-estrogenized), 2 (poorly estrogenized), or 3 (combination) mucosae. Other outcomes assessed included symptom severity (visual analog scale for symptoms including most bothersome symptom, and Vulvovaginal Symptom Questionnaire) and Vaginal Health Index. Prespecified secondary analyses of data were performed. Categorical data were analyzed using the Pearson chi-square test (or Fisher exact test if <5 in any category) or related-samples McNemar test for paired nonparametric data. Nonparametric, continuous variables were assessed using Wilcoxon signed-rank test or Mann-Whitney U test, and parametric variables with t test or 1-way analysis of variance as appropriate. All analyses were performed using SPSS software version 26.0 (IBM Corp, Armonk, NY). RESULTS: There was no significant difference in microscopic features of vaginal epithelium following laser or sham treatment (P=.20). Further subgroup analyses of age, menopause type, duration of reproductive life, time since menopause and BMI, still demonstrated no significant difference between laser and sham groups in histological category of vaginal epithelium. Microscopic features at pre-treatment vaginal biopsy were Type 1 in 27% (13/49). There was no significant difference in VAS score for overall vaginal symptom between those classified as Type 1 vs. Type 2/3 (VAS score overall: Type 1 vs. Type 2/3, (48.1 [95% CI 27.0, 69.2] vs. 61.5 [95% CI 49.8, 73.3]; P=.166). CONCLUSION: Data from this double-blind, sham-controlled randomized controlled trial demonstrate that fractional CO2 laser and sham treatment have a comparable histologic effect on vaginal tissue that is not significantly different. Fractional CO2 laser is not significantly different from sham treatment and should not be recommended for clinical use for postmenopausal vaginal symptoms.


Asunto(s)
Láseres de Gas , Enfermedades Vaginales , Femenino , Humanos , Posmenopausia , Dióxido de Carbono/uso terapéutico , Calidad de Vida , Vagina/cirugía , Vagina/patología , Enfermedades Vaginales/diagnóstico , Láseres de Gas/uso terapéutico , Resultado del Tratamiento
17.
Naunyn Schmiedebergs Arch Pharmacol ; 396(10): 2729-2739, 2023 10.
Artículo en Inglés | MEDLINE | ID: mdl-37126195

RESUMEN

The digestive system is exposed to severe inflammation as a result of taking some medications that have gastrointestinal side effects. Sixty Swiss-albino male mice were randomly distributed into six groups to treat inflammations of the colon, stomach, and small intestine caused by taking high doses of diclofenac (D), with two novel synthesized compounds, pyrazolo [3,4 d] pyridazine derivatives (Co1 and Co2). Myeloperoxidase enzyme activity was determined in the colon and small intestinal tissues. Serum contents of TNF-α, IL-22, IgG, and IgM were determined by ELISA. Histopathological examinations of the colon, small intestinal, and stomach tissues were microscopically analyzed. TNF-α, IL-22, and TNFSF11 gene expression were measured in the colon, intestinal, and spleen using qRT-PCR. Diclofenac caused surface columnar epithelial cell loss, focal necrosis of the gastric mucosa, inflammatory cell infiltration, and congested blood vessels in the stomach, colon, and small intestinal tissues. Co1 component was found to be better than Co2 component in reducing the focal necrosis of gastric mucosa and improving the histological structures of the stomach, colon, and small intestinal tissues. After 14 days, the activity of the myeloperoxidase enzyme was increased in group D and decreased in groups DCo1, DCo2, Co1, and Co2. Serum concentrations of TNF-α and IgG were increased, while IL-22 and IGM were reduced in the D, DCo1, and DCo2 groups compared with the Co1 and control groups. TNF-α gene was upregulated in the D group and downregulated in the Co1 group, while the IL-22 gene was downregulated in the D group and upregulated in the Co1 group compared with the control group. The CO1 component may be useful in reducing digestive system inflammation.


Asunto(s)
Colitis , Ratones , Animales , Colitis/tratamiento farmacológico , Peroxidasa/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Diclofenaco/farmacología , Dióxido de Carbono/metabolismo , Dióxido de Carbono/farmacología , Dióxido de Carbono/uso terapéutico , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Inflamación/patología , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Colon , Antioxidantes/farmacología , Necrosis/tratamiento farmacológico , Necrosis/metabolismo , Necrosis/patología , Inmunoglobulina G/metabolismo , Inmunoglobulina G/farmacología , Inmunoglobulina G/uso terapéutico , Inmunoglobulina M/metabolismo , Inmunoglobulina M/farmacología , Inmunoglobulina M/uso terapéutico , Modelos Animales de Enfermedad
18.
Lasers Surg Med ; 55(7): 642-652, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37222180

RESUMEN

OBJECTIVES: Actinic keratosis have a high risk of progression to a squamous cell carcinoma. Insulin-like growth factor 1 and its receptor play a relevant role in restoring repair of ultraviolet-induced cell damage. This pathway is reduced in patients older than 65 years. Ablative fractional laser resurfacing could normalize insulin-like growth factor 1 (IGF-1) secretion in elderly by recruiting new fibroblasts. The aim of the study is to evaluate restoration of IGF1 values by PCR in senescent fibroblasts after ablative fractional laser resurfacing. METHODS: We enrolled 30 male patients with multiple actinic keratosis on the scalp, equally divided into two mirror areas of up to 50 cm2 , treating only the right one. We performed one skin biopsy for each area 30 days after treatment. Real-time PCR in fibroblasts was performed to assess the change in IGF1. At baseline and after 6 months, in vivo reflectance confocal microscopy examination was performed in all patients. RESULTS: IGF1 values were increased in the treated side by about 60%. The right areas had fairly complete resolution of actinic keratosis at the last follow-up visit after 6 months with no appearance of new lesions. The mean number of actinic keratosis in the right area was reduced by more than 75% at four- and six-follow-up visits compared to the left area. The improvement in the right area was also evidenced by lower values of the mean AKASI (actinic keratosis area and severity index) score. Reflectance confocal microscopy showed a reduction of keratinocytic disarray and scales after treatment. DISCUSSION: Taken together, all the clinical, laboratory, and in vivo results of our study allowed us to confirm that ablative fractional laser resurfacing is a valuable tool for the treatment of actinic keratosis and cancerization field, both for the management of clinically evident lesions and for preventing the occurrence of squamous cell carcinoma.


Asunto(s)
Carcinoma de Células Escamosas , Queratosis Actínica , Humanos , Masculino , Anciano , Queratosis Actínica/tratamiento farmacológico , Factor I del Crecimiento Similar a la Insulina/uso terapéutico , Dióxido de Carbono/uso terapéutico , Cuero Cabelludo , Carcinoma de Células Escamosas/radioterapia , Carcinoma de Células Escamosas/cirugía , Rayos Láser , Resultado del Tratamiento
19.
CNS Neurosci Ther ; 29(11): 3378-3390, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37208955

RESUMEN

AIMS: Few treatments are available in the subacute phase of traumatic brain injury (TBI) except rehabilitation training. We previously reported that transient CO2 inhalation applied within minutes after reperfusion has neuroprotective effects against cerebral ischemia/reperfusion injury. In this study, it was hypothesized that delayed CO2 postconditioning (DCPC) starting at the subacute phase may promote neurological recovery of TBI. METHODS: Using a cryogenic TBI (cTBI) model, mice received DCPC daily by inhaling 5%/10%/20% CO2 for various time-courses (one/two/three cycles of 10-min inhalation/10-min break) at Days 3-7, 3-14 or 7-18 after cTBI. Beam walking and gait tests were used to assess the effect of DCPC. Lesion size, expression of GAP-43 and synaptophysin, amoeboid microglia number and glia scar area were detected. Transcriptome and recombinant interferon regulatory factor 7 (Irf7) adeno-associated virus were applied to investigate the molecular mechanisms. RESULTS: DCPC significantly promoted recovery of motor function in a concentration and time-course dependent manner with a wide therapeutic time window of at least 7 days after cTBI. The beneficial effects of DCPC were blocked by intracerebroventricular injection of NaHCO3 . DCPC also increased puncta density of GAP-43 and synaptophysin, and reduced amoeboid microglia number and glial scar formation in the cortex surrounding the lesion. Transcriptome analysis showed many inflammation-related genes and pathways were altered by DCPC, and Irf7 was a hub gene, while overexpression of IRF7 blocked the motor function improvement of DCPC. CONCLUSIONS: We first showed that DCPC promoted functional recovery and brain tissue repair, which opens a new therapeutic time window of postconditioning for TBI. Inhibition of IRF7 is a key molecular mechanism for the beneficial effects of DCPC, and IRF7 may be a potential therapeutic target for rehabilitation after TBI.


Asunto(s)
Lesiones Traumáticas del Encéfalo , Dióxido de Carbono , Factor 7 Regulador del Interferón , Animales , Ratones , Lesiones Traumáticas del Encéfalo/metabolismo , Dióxido de Carbono/metabolismo , Dióxido de Carbono/uso terapéutico , Modelos Animales de Enfermedad , Proteína GAP-43/metabolismo , Factor 7 Regulador del Interferón/metabolismo , Factor 7 Regulador del Interferón/uso terapéutico , Sinaptofisina/metabolismo , Sinaptofisina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...